OXYLONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OXYLONE (OXYLONE).
Corticosteroid that binds to glucocorticoid receptors, modulating transcription of anti-inflammatory proteins and suppressing immune response.
| Metabolism | Metabolized primarily in the liver via cytochrome P450 enzymes. |
| Excretion | Renal: 70-90% (as metabolites, mainly 6β-hydroxycortisol and other conjugates); Biliary/fecal: <10%; Unchanged drug: <5% in urine. |
| Half-life | Terminal elimination half-life: 1.5-2.5 hours. Clinical context: Short half-life necessitates multiple daily dosing for sustained anti-inflammatory effect; accumulation minimal with repeated dosing. |
| Protein binding | Corticosteroid-binding globulin (CBG) 90-95%; Albumin 5-10%; total bound 95-98%. |
| Volume of Distribution | 0.4-0.6 L/kg. Clinical meaning: Moderate distribution consistent with high protein binding; does not extensively distribute into tissues. |
| Bioavailability | Oral: 70-90% (due to extensive first-pass metabolism in liver); Topical: 1-5% (varies with skin condition and formulation); Intramuscular: 100%; Intravenous: 100%. |
| Onset of Action | Oral: 2-4 hours; Topical: 1-2 hours; Intramuscular: 4-6 hours; Intravenous: immediate (within minutes). |
| Duration of Action | Oral: 30-36 hours (clinical duration due to delayed receptor-mediated effects); Topical: 8-12 hours per application; Intramuscular: 24-48 hours; Intravenous: 12-24 hours. Note: Duration longer than half-life due to intracellular persistence. |
Apply topically to affected area twice daily.
| Dosage form | CREAM |
| Renal impairment | No adjustment required as systemic absorption is minimal. |
| Liver impairment | No adjustment required as systemic absorption is minimal. |
| Pediatric use | Use smallest amount for shortest duration; avoid prolonged use. |
| Geriatric use | Use with caution; skin thinning and increased systemic absorption risk. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OXYLONE (OXYLONE).
| Breastfeeding | Corticosteroids are excreted in breast milk. Fluorometholone M/P ratio not available. Short-term, low-dose ophthalmic use likely minimal systemic absorption. Avoid breastfeeding for 2 hours after topical administration. Systemic use may suppress infant adrenal function. |
| Teratogenic Risk | Oxylone (fluorometholone) is a corticosteroid. In the first trimester, systemic corticosteroids are associated with a small increased risk of cleft palate. Second and third trimester exposure may increase risk of intrauterine growth restriction and adrenal insufficiency in the neonate. Use only if benefit outweighs risk. |
■ FDA Black Box Warning
Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.
| Serious Effects |
["Hypersensitivity to any component of the formulation","Untreated bacterial, fungal, viral, or tuberculous skin infections"]
| Precautions | ["HPA axis suppression with prolonged use, especially in children and with occlusive dressings","Local adverse reactions including atrophy, striae, and telangiectasias","Potential for systemic effects if used on large areas or under occlusion","Use with caution in patients with skin infections"] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of adrenal suppression in mother and neonate if systemic exposure. In prolonged use, assess for intrauterine growth restriction via ultrasound. Monitor neonatal cortisol levels if maternal systemic exposure near term. |
| Fertility Effects | No specific human studies; animal studies show no effect on fertility with fluorometholone. Systemic corticosteroids may alter menstrual cycle and sperm count at high doses; clinical significance unknown. |